

1 **TITLE**

2 ***Dolutegravir-related hyperglycemia among children and adolescents <18 years in Northern and***
3 ***Eastern Uganda: A cross-sectional study***

4
5 **Authors:** Fridah Akello^{1*}, Damalie Nalwanga^{1,3} Victor Musiime^{1,2}, Sarah Kiguli¹
6 **Institutions:**

7 1. Department of Paediatrics and Child Health, School of Medicine, College of Health Sciences,
8 Makerere University, P.O.Box, 7072, Kampala, Uganda.

9 2. Joint Clinical Research Center, Kampala, Uganda

10 3. Makerere Lung Institute, Kampala, Uganda

11 * Corresponding author **email address:** fridah.akello@gmail.com

12

13

14

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

ABSTRACT

Background: The World Health Organization (WHO) recommended Dolutegravir (DTG) as the preferred anchor drug for first and second line Anti-Retroviral Treatment (ART) regimen. Case reports and studies have demonstrated new onset hyperglycemia among adults initiated or transitioned to DTG. There is paucity of data on DTG-related hyperglycemia among children and adolescents and subsequently, glycemic screening is not routinely conducted for those using DTG. We determined the prevalence and factors associated with DTG-related hyperglycemia in this age category.

Methods: This cross-sectional study was conducted from 28th October 2022 to 11th September 2023 at Soroti and Lira Regional Referral Hospitals. 251 children and adolescents under 18 years, on a DTG based ART regimen, were consecutively enrolled and data analyzed for 240 participants. Socio-demographic, anthropometric measurements, clinical, and laboratory variables were collected using a questionnaire. Random blood glucose testing, urine dipstick and HbA1c analyses were conducted. Data was entered into epiData version 4.6, cleaned, and analyzed using STATA version 17.0. Logistic regression was used to determine the relationship between outcome and predictor variables. A p-value < 0.05 was considered statistically significant at multivariate analysis.

Results: Of the 240 study participants, 55.4 % (n=133) were female and 71.7 % (n =172) were over 10 years. The prevalence of DTG-related-hyperglycemia was 20% (n=49) and 95.9% (n=47) met the criteria for pre-diabetes. Health education talks on Adverse events related to Dolutegravir was protective for hyperglycemia (**aOR 0.4, 95% CI 0.2-0.9**), **p = 0.035**.

Conclusion: The prevalence of DTG-related-hyperglycemia was high, occurring in every 2 in 10 children and adolescents. Health education talks on adverse events associated with DTG use

38 were found to be protective against hyperglycemia. Routine glyceimic screening and monitoring
39 therefore should be emphasized. Additionally, a strategy for health education talks focusing on
40 lifestyle modifications to reduce the occurrence of hyperglycemia should be developed.

41 **Key words:** Hyperglycemia, Dolutegravir

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61 **Introduction**

62 The world Health Organization and Ministry of Health recommended Dolutegravir (DTG), an
63 Integrase Strand Transfer Inhibitor (INSTI) as the preferred anchor drug for first and second line
64 HIV treatment options (1). This was supported by study results from the ODYSSEY (Once-daily
65 Dolutegravir based ART in Young people versus Standard Therapy) and Penta-17 trials that
66 showed Dolutegravir to be superior to the current standard of care ART regimen (predominantly
67 a Protease Inhibitor based-ART) in children and adolescents (2).

68 Subsequently, all eligible persons living with HIV are being initiated or optimized to a DTG
69 containing regimen however, a number of case reports and studies among adult patients
70 document symptomatic hyperglycemia associated with initiation on DTG (3–5). Hyperglycemia
71 is defined as a fasting blood glucose level of >7.0 mmol/L or a random plasma glucose greater
72 than 11.1 mmol/L and or an HBA1C level $>6.5\%$ (6). The prediabetes state defined by the
73 American Diabetic association as a state of intermediate hyperglycemia based on blood glucose
74 levels or estimates of glycated haemoglobin levels is also considered hyperglycemia.

75 DTG is postulated to cause hyperglycemia through chelation of magnesium to prevent HIV from
76 integrating into host DNA(7,8). Because magnesium serves as a cofactor in post-receptor insulin
77 action, Magnesium chelation may cause disorders of glucose metabolism (9,10). In addition,
78 concomitant HIV infection is associated with insulin resistance resulting from immune activation
79 and chronic inflammation thus worsening the hyperglycemia (11).

80 Despite these isolated study findings, there is paucity of data on DTG associated hyperglycemia
81 and even more particularly in the pediatric and adolescent population. Hyperglycemia if
82 undetected or managed late poses severe acute complications including Diabetic Ketoacidosis

83 (DKA) and Hyperosmolar Hyperglycemic State (HHS) (12). Chronic complications are related
84 to the micro vascular changes which predispose to retinopathy, nephropathy and neuropathy
85 resulting from cellular damage inflicted by the hyperglycemia (13).
86 Ministry of Health (MoH) Uganda HIV treatment guidelines (2022) recommend routine
87 monitoring for therapeutic response and drug related adverse events for all children and
88 adolescents on ART however glycemic monitoring is not specifically mentioned. In contrast
89 however, baseline random blood sugar testing and routine monitoring for adults over 45 years is
90 emphasized in these treatment guidelines. (14). Furthermore, there is scanty data on prevalence
91 and factors associated with DTG-related-hyperglycemia among children and adolescents in
92 Uganda and this study addressed this knowledge gap. Findings from this study form a point of
93 reference for additional studies and guidelines to improve adverse events monitoring for children
94 and adolescents on DTG.

95 **Methods**

96 **Study site**

97 This was conducted at the HIV clinics of Soroti and Lira Regional Referral Hospitals (RRHs)
98 both tertiary level health care facilities in Eastern and Northern Uganda respectively. Soroti RRH
99 was the primary study site and Lira RRH was included as an additional site having reached
100 saturation in Soroti. Lira RRH was chosen owing to its homogeneity to Soroti in regard to
101 dietary and activity characteristics of the population. Both regions were ravaged by the 5 year
102 LRA war in 2002-2006 and resultantly bore the brunt of the HIV epidemic with relatively high
103 rates of HIV transmission. Each of the hospitals has one of the largest pediatric HIV enrollments
104 in the respective regions and subsequently, a high number of children and adolescents on a DTG
105 based ART regimen. Soroti RRH serves a catchment area with a population of 2.7 million

106 persons. Lira RRH on the other hand offers general and specialized health care services to a
107 population of close to 2.3 million individuals from the 9 districts of Lango sub-region.

108 **Study population and sample size determination**

109 These were all children and adolescents below 18 years on a DTG containing regimen for at least
110 6 months attending the paediatric HIV clinics of Soroti and Lira RRHs. The study was conducted
111 from 28th October 2022 to 11th September 2023. The sample size of 240 was determined using
112 the Kish Leslie and Fleiss formulae.

113 **Study design and data collection procedure**

114 The study used a cross sectional study design. Quantitative data was collected using a
115 questionnaire onto which socio-demographic information, anthropometry and relevant history
116 were captured.

117 **Inclusion and exclusion criteria**

118 We included all participants below 18 years, on a DTG based regimen for at least 6 months with
119 documented good adherence in the last 4 months and excluded those who had an acute illness, a
120 past history of hyperglycemia or if they declined to consent or assent.

121 **Study variables**

122 The dependent variable was hyperglycemia defined as a random plasma glucose concentration of
123 ≥ 11.1 mmol/l (200 mg/dl) or an HbA1c of $> 6.5\%$ (15). Patients with prediabetic glyemic
124 levels were also considered to have hyperglycemia. This was determined by a random plasma
125 glucose of 7.8-11.0 mmol/L or an HBA1C of 5.7-6.4%.

126 Independent variables included patient factors like age, sex, current and pretreatment Body Mass
127 Index (BMI) for age z scores, Pre-existing comorbidities, Age at diagnosis of HIV, Age at ART
128 initiation, Use of other medications, WHO Stage, Duration on ART, Duration on DTG and most

129 recent viral load. Health system factors included Glycemic screening, patient Education on DTG
130 Adverse Events and Glycemic Monitoring

131 **Data management and analysis**

132 Data was entered into EpiData (v4.6) and exported to STATA version 17 for analysis. Univariate
133 analysis was done for socio-demographic and baseline clinical characteristics and was presented
134 in form of frequencies, proportions and means. A bivariate analysis was performed to determine
135 the association between the dependent and independent variables. Variables with p values <0.2
136 were considered for multivariate analysis. A logistic regression was then performed to determine
137 the statistical significance of the association between these variables and hyperglycemia. Factors
138 with P values <0.05 were considered statistically significant.

139 **Ethical consideration**

140 The study protocol was approved by the School of Medicine Research and Ethics Committee
141 (SOMREC), reference number Mak-SOMREC-2022-405. Administrative clearance was further
142 obtained from the hospital directors and research committees of Soroti and Lira RRHs. Parental
143 consent was obtained for participants below 8 years while assent was obtained for participants 8
144 years and above and substantiated by a witness within the clinic. All consent was written and
145 documented on a parental consent or assent form as applicable.

146 **Results**

147 **Participant Demographic and baseline clinical characteristics**

148 Data was analyzed for 240 participants. Mean age was 12.36 ±3.76 years. Females accounted for
149 55.4% (n=133) and 71.7% (n=172) were over 10 years of age. Median age at HIV diagnosis was
150 24.06 (IQR, 1.33-46.79) months. Majority of participants, 202 (84.2%), had been on ART for more

151 than 5 years, only 37.9% (n=91) had been on a DTG-containing regimen for more than 2 years
 152 while 68.8% (n=165) initiated ART before the age of five years s presented in **Table 1** below.

153 **Table 1: Demographic and baseline clinical characteristics of study participants**

Variable	Total n=240	Percentage (%)
Age (Years)		
1-4	10	4.2
5-10	58	24.2
>10	172	71.7
Sex		
Female	133	55.4
Male	107	44.6
Age at ART STAT (Years)		
0-4	165	68.8
5-10	62	25.8
>10	13	5.4
Duration on ART(Years)		
<1	4	1.7
1-5	34	14.2
>5	202	84.2
Duration on DTG		
<1	26	10.8
1-2	123	51.3
>2	91	37.9
Baseline CD4		
<100 cells/mm ³	6	2.5
100 <250 cells/mm ³	8	3.3
250-500 cells/ mm ³	16	6.7
>500 cells/ mm ³	37	15.4
Unknown	173	72.1
Baseline ART		
NVP based	128	53.3
EFV based	60	25.0
PI based	40	16.7
DTG	12	5.0
WHO Stage at ART initiation		
Stage I	177	73.8
Stage II	29	12.1
Stage III	26	10.8
Stage IV	8	3.3
BMI for age z scores at DTG initiation		
Normal	197	82.1
Overweight	10	4.2
Underweight	11	4.6
Not assessed	22	9.1

Abbreviations: NVP Nevirapine EFV Efavirenz PI Protease Inhibitor

154 Only 37.9% (n=67) had results for baseline CD4 counts, of which 5.8% (n=14) had a CD4 count
155 below 250 cells/mm³. Approximately 53.3% (n=128) of the study participants initially received
156 Nevirapine as baseline ART, and only 5.0% (n=12) were initiated on a DTG-based regimen.
157 Significantly, 73.8% (n=177) of the participants were classified as WHO stage I at the initiation
158 of ART, however, upon the most recent WHO clinical staging, this percentage notably increased
159 to 94.6%, highlighting substantial clinical improvement in the study population.

160 **Recent clinical characteristics of study participants**

161 Majority of clients, 92.1% (n=221), were still on a first-line ART regimen. Specifically, 62.9%
162 (n=151) of participants are on a Tenofovir-based ART drug combination as in *Table 2* below.

163 *Table 2: Recent clinical characteristics of study participants*

Variable	Total n=240	Percentage (%)
Current regimen line		
1st Line	221	92.1
2nd Line	17	7.1
3rd Line	2	0.8
Current ART Regimen		
ABC based	80	33.3
TDF Based	151	62.9
AZT Based	8	3.3
PI and NRTI based	1	0.4
Viral Load		
Suppressed	199	82.9
Non suppressed	38	15.8
Not done	3	1.3
Current BMI for age z scores		
Normal	205	85.4
Overweight	12	5.0
Underweight	23	9.6
Recent WHO stage		
Stage I	227	94.6
Stage II	10	4.2
Stage III	2	0.8
Stage IV	1	0.4

164

165 Only 2 (0.9%) participants, have transitioned to a third-line ART regimen. It is noteworthy that
166 only 82.9% of the participants had achieved virological suppression, defined as having a viral load
167 less than 1000 copies/ml.

168 Additionally, 85.4% (n=205) of the participants had normal body mass index (BMI) for age z-
169 scores and there were notably no significant changes in BMI for age z-scores between the
170 initiation of DTG and recent measurements.

171 **Prevalence of Dolutegravir-related-hyperglycemia**

172 A participant was considered to have hyperglycemia if either their RBS measurement was
173 greater than 7.8 mmol/L or their HbA1c level was equal to or greater than 5.7%. This inclusive
174 definition also encompassed the prediabetes state.

175 Overall, the findings revealed that 49 (20%) [95% CI 0.1506, 0.2578] study participants had
176 hyperglycemia. Notably, HbA1C levels varied from 3.5% - 6.7%.

177 Among those diagnosed with hyperglycemia, HbA1c alone was responsible for identifying
178 hyperglycemia in the majority, with 46 (93.9%) participants diagnosed using this measure.

179 Conversely, only a small proportion, 3 (6.1%), were identified as hyperglycemic based on the
180 RBS measurement alone. Only two participants had diabetic range HbA1C levels.

181 **Patient factors associated with DTG-related-hyperglycemia**

182 At bivariate analysis for the clinical characteristics of study participants, age, duration on DTG
183 and baseline CD4 had P values <0.2 and were considered for the multivariate analysis as shown
184 in **Table 3** below.

185 *Table 3: Patient factors associated with DTG-related-hyperglycemia*

Variable	Hyperglycemia		Crude OR (95% CI)	P Value
	No n=191 (80%)	Yes n=49 (20%)		
Current regimen line				0.071*
1st Line	172(77.8)	49(22.2)	1	
2nd Line	17(100.0)	0(0.0)	0.1(0.01, 1.7)	0.110
3rd Line	2(100.0)	0(0.0)	0.7(0.03, 14.8)	0.817
Current ART Regimen				0.172*
ABC based	70(87.5)	10(12.5)	1	
TDF Based	114(75.5)	37(24.5)	2.2(1.04, 4.6)	0.038*
AZT Based	6(75.0)	2(25.0)	2.6(0.5, 12.7)	0.244
PI and NRTI based	1(100.0)	0(0.0)	2.2(0.1, 58.6)	0.629
Viral Load				0.308
Suppressed	155(77.9)	44(22.1)	1	
Non suppressed	33(86.8)	5(13.2)	0.6(0.2, 1.5)	0.257
Not done	3(100.0)	0(0.0)	-	
Current BMI for age z scores				0.791
Normal	165(80.5)	40(19.5)	1	
Overweight	8(66.7)	4(33.3)	2.2(0.7, 7.1)	0.205
Underweight	18(78.3)	5(21.7)	1.2(0.4, 3.3)	0.706
Total	165(80.5)	40(19.5)		
Recent WHO stage				0.854
Stage I	180(79.3)	47(20.7)	1	
Stage II	8(80.0)	2(20.0)	1.1(0.3, 4.7)	0.880
Stage IV	2(100.0)	0(0.0)	0.8(0.04, 16.1)	0.860
Not staged	1(100.0)	0(0.0)	1.3(0.01, 31.6)	0.885
Herbal Remedies				0.129*
No	174(80.9)	41(19.1)	1	
Yes	17(68.0)	8(32.0)	2.0(0.8, 5.0)	0.114
History suggesting hyperglycemia				0.001*
Polyuria	3(100.0)	0(0.0)	-	
Polydipsia	0(0.0)	3(100.0)	-	
Polyphagia	0(0.0)	1(100.0)	-	
None	188(80.7)	45(19.3)	-	
Family History of HTN				0.035*
No	178(81.3)	41(18.7)	1	
Yes	13(61.9)	8(38.1)	2.7(1.1, 6.8)	0.034

186 A subset of study participants, 25 (11.7%), reported a history of using herbal remedies and only
 187 8 (32%) were found to have hyperglycemia. Majority of study participants 233 (97.1%) did not
 188 have any history suggestive of hyperglycemia and only 21 (8.8%) had a family history of
 189 hypertension.

190 At bivariate analysis, current regimen line, current ART regimen, history of use of herbal
 191 remedies and family history of hypertension was considered for multivariate analysis.

192 **Health system factors associated with DTG-related-hyperglycemia**

193 According to the study data, only 45(18.8%) participants had a baseline random blood sugar
 194 done at initiation of DTG while 169 (70.4%) had never received any form of glycemie
 195 monitoring. The majority of participants, 60.4% had not received a health education talk on DTG
 196 related adverse events and only 54.6% were aware of reporting avenues for DTG related adverse
 197 events. This is summarized in *Table 4* below.

198 **Table 4: Health System factors associated with DTG-related-hyperglycemia**

Variable	Hyperglycemia			Crude OR (95% CI)	P value
	Total	No n=191(80%)	Yes n=49 (20%)		
Base line BGL at DTG Start					
Not done	195(81.3)	147(75.4)	48(24.6)	1	0.008*
Normal	44(18.3)	43(97.7)	1(2.3)	0.1(0.01, 0.6)	
Elevated	1(0.4)	1(100.0)	0(0.0)	-	
BGL Monitoring on DTG					
Never	169(70.4)	125(74.0)	44(26.0)	1	0.033
once	48(20.0)	43(89.6)	5(10.4)	0.4[0.1, 0.9]	
More than once	23(9.6)	23(100.0)	0(0.0)	0.1[0.04, 1.01]	
Health Education on DTG AEs					
No	145(60.4)	105(72.4)	40(27.6)	1	0.001*
Yes	95(39.6)	86(90.5)	9(9.5)	0.3[0.1, 0.6]	
Awareness of DTG AE reporting avenues					
No	109(45.4)	90(82.6)	19(17.4)	1	0.305
Yes	131(54.6)	101(77.1)	30(22.9)	0.3(0.1, 0.6)	

Abbreviations: BGL: Blood glucose level AE: Adverse events

199 The bivariate analysis in this study showed that there were significant associations between
 200 glycemie monitoring and health education talks on DTG side effects with the occurrence of
 201 hyperglycemia. Participants who had their plasma glucose levels monitored at least once had a
 202 lower likelihood of developing hyperglycemia, (OR 0.4, 95% CI, 0.1-0.9) P = 0.033.

203 Similarly participants who had received a health education talk on the side effects of DTG had a
 204 lower likelihood of developing hyperglycemia (OR 0.3, 95% CI, 0.1-0.6), P=0.001.

205 **Multivariate analysis of factors associated with DTG-related-hyperglycemia**

206 At multivariate analysis, only Health Education on Dolutegravir associated adverse events was
 207 found to have a statistically significant association with developing DTG-related hyperglycemia
 208 as summarized in *Table 5* below.

209 *Table 5: Multivariate analysis of factors associated with Dolutegravir-related-hyperglycemia*

Variables	COR[95% conf. interval]	P-value	AOR[95% conf. interval]	P-values
Duration on DTG[Years]				
<1	1		1	
1-2	2.4[0.7, 7.8]	0.158	2.1[0.6, 7.3]	0.234
>2	1.3[0.4, 4.5]	0.707	1.2[0.3, 4.7]	0.748
Current ART Regimen				
ABC based	1		1	
TDF Based	2.2[1.04, 4.6]	0.038	2.1[0.9, 4.6]	0.073
AZT Based	2.6[0.5, 12.7]	0.244	3.4[0.6, 18.7]	0.153
PI and NRTI based	2.2[0.1, 58.6]	0.629	5.6[0.2, 170.8]	0.326
Family History of HTN				
No	1		1	
Yes	2.7[1.1, 6.8]	0.034	1.6[0.6, 4.2]	0.358
BGL Monitoring on DTG				
Never	1		1	
once	0.4[0.1, 0.9]	0.033	0.4[0.2, 1.2]	0.101
More than once	0.1[0.04, 1.01]	0.051	0.1[0.01, 1.7]	0.113
Health Education on DTG AEs				
No	1		1	
Yes	0.3[0.1, 0.6]	0.001	0.4[0.2, 0.9]	0.035

210 **Abbreviations:** AEs, Adverse events HTN Hypertension ABC Abacavir TDF Tenofovir AZT Zidovudine PI

211 *Protease Inhibitor*

212 After adjusting for other factors, participants who had health education talks on DTG-related-
 213 hyperglycemia were 60% less likely to develop hyperglycemia compared to those who did not
 214 receive any (AOR 0.4, 95% CI, 0.2-0.9, P = 0.035).

215 **Discussion**

216 This cross-sectional study determined the prevalence and factors associated with Dolutegravir-
217 related hyperglycemia among children and adolescents in two regional referral hospitals in
218 Uganda. The study included a total of 240 participants from Soroti RRH and additional
219 participants from Lira Regional Referral Hospital.

220 Hyperglycemic status was determined based on elevated random blood sugar or glycated
221 hemoglobin levels. The study suggested an association between the use of a Dolutegravir-
222 containing ART regimen and hyperglycemia.

223 The study findings reveal that among children and adolescents on a DTG-based ART regimen,
224 the prevalence of hyperglycemia was 20%, indicating that approximately two out of every 10
225 children were affected.

226 Furthermore, the prevalence of prediabetes and diabetic range hyperglycemia was 17.9% and
227 2.1% respectively. This prevalence is higher compared to the estimated rates of prediabetes and
228 diabetes in the broader African region, which is reported to be 8.6% and 3.3% respectively (16).
229 The difference in prevalence could be attributed to the specific population studied (children and
230 adolescents on DTG-based ART) who have an additional risk factor of HIV infection, which is
231 known to be associated with an increased risk of hyperglycemia.

232 Results from a similar study conducted in Botswana by Moverman *et al.*; showed the prevalence
233 of prediabetes and diabetic range hyperglycemia in the general population of persons living with
234 HIV to be 30% and 6% respectively(17). The lower prevalence in our study can be explained by
235 the fact that the former study was conducted in a population of older adults who were over 40
236 years age and therefore had additional risk factors for hyperglycemia associated with older age.

237 It is important to highlight that there is currently no published data available on the prevalence of
238 DTG-related hyperglycemia specifically in the child and adolescent age group. Abera *et al*; in
239 2022 reported a prevalence of 14.7% among adult patients attending a tertiary hospital in
240 Ethiopia. The higher prevalence in our study could be attributed to the inclusion of prediabetic
241 HbA1C levels as part of the criteria for hyperglycemia in the current study, which was not
242 considered in the Ethiopian study. This suggests that prediabetic states may contribute to the
243 higher prevalence observed in the child and adolescent population.

244 In contrast, Odenyo *et al*; in 2020 reported a prevalence of 55.9% in their study conducted in an
245 adult population in a Kenyan hospital(18). These findings may be attributed to the presence of
246 additional risk factors in the adult age group like insulin resistance, impaired glucose tolerance,
247 or age-related changes in metabolism that predisposes them to an increased risk of developing
248 hyperglycemia.

249 Related studies include one by Bahamdain *et al*; in Arizona where 7% of adult study participants
250 met the criteria for prediabetes 3-6 months after DTG initiation(19). However, in the current
251 study, due to the cross-sectional study design, the survival time to developing prediabetes could
252 not be determined. In addition, Namara *et al*; in their case control study in Uganda, reported that
253 adults who had been previously exposed to a Dolutegravir-containing regimen had seven times
254 higher odds of developing hyperglycemia compared to those with no history of exposure (20).

255 Dolutegravir has been postulated to cause hyperglycemia by a mechanism involving chelation of
256 Magnesium which is critical for the action of viral integrase enzyme in the HIV replication cycle.
257 These study findings should therefore be of great concern since current WHO and MoH-Uganda
258 HIV care and treatment guidelines only emphasize DTG glycemic screening and monitoring for
259 mainly adults over 45 years who are perceived to be at risk for hyperglycemia overlooking the

260 potential risk to children and adolescents which is probably based on an assumption that children
261 and adolescents are usually euglycemic. These findings thus suggest that the prevalence of
262 Dolutegravir-related hyperglycemia can vary across different populations and age groups.

263 At bivariate analysis, a number of factors were found to be associated with hyperglycemia and
264 these included a history of using a TDF based ART regimen, family history of hypertension and
265 history of health education on adverse events associated with DTG use.

266 Children and adolescents who received health education on the side effects of Dolutegravir were
267 less likely to develop hyperglycemia cOR 0.3 ($p = 0.001$). Furthermore, at multivariate analysis,
268 after adjusting for other factors, health education talks remained significantly protective against
269 DTG-related hyperglycemia, with (aOR) of 0.4 ($p = 0.035$). This could be attributed to the fact
270 that currently, facility based education sessions are also geared towards control of Non
271 communicable Diseases (NCDs) with emphasis on enhancement of lifestyle modifications
272 protective for diabetes and hypertension.

273 There has been a remarkable paradigm shift in the content of health education talks. Early at the
274 start of the HIV epidemic, health education talks were focused on stigma reduction, adherence
275 and disclosure however owing to the success of the ART program, PLHIV are living longer and
276 faced with higher risk for NCDs given the additional risk posed by the HIV infection and the anti
277 HIV drugs. The focus of health education sessions has had to include modalities for screening
278 and prevention of NCDs.

279 Fitch *et al*; 2006 in their study demonstrated that weekly counseling by a dietician with main
280 emphasis on healthy eating, rather than weight loss, was associated with a significant reduction
281 in blood pressure, waist circumference and HbA1c (21). In addition, endurance and resistance

282 exercises have also been shown to have positive effects on metabolic parameters in HIV infected
283 patients (22) therefore health education messages that highlight such lifestyle modifications are
284 protective for hyperglycemia.

285 Other studies have shown that effective health education improves knowledge, attitude, and
286 practices, particularly with regard to lifestyle modifications and dietary management,
287 culminating into better glycemic control that can slow down the progression of diabetes and
288 prevent downstream complications (23).

289 These findings thus highlight the importance of health education in reducing the risk of
290 hyperglycemia in individuals using DTG.

291 The study did not reveal any statistically significant association between hyperglycemia and sex,
292 BMI for age z scores, duration on Dolutegravir, WHO stage, baseline CD4 counts, and the use of
293 herbal drug remedies. These findings differ from previous studies that have reported associations
294 between these factors and Dolutegravir-related hyperglycemia. For example, Odenyo *et al*;
295 found that females were 1.6 times more likely to develop DTG-related hyperglycemia (18),
296 while Miiro *et al*; and Abera *et al*; reported that males were more likely to develop
297 hyperglycemia (24,25). Additionally, Odenyo *et al*; found that overweight patients were 1.7
298 times more likely to develop hyperglycemia. In terms of BMI for age z scores, the current study's
299 findings align with studies by Namara *et al*; and the GLUMED study in Kampala, which also did
300 not find a significant association between BMI and hyperglycemia (20,26). The duration on
301 Dolutegravir also did not show a statistically significant association with hyperglycemia in
302 contrast to the findings by Lamorde *et al*; in Uganda (5). Similarly, factors such as WHO stage,
303 baseline CD4 counts, and the use of herbal drug remedies also did not demonstrate a significant
304 association with hyperglycemia in the current study.

305 **Strength of the study**

306 This is among the few studies in Uganda to investigate the prevalence of DTG-related
307 hyperglycemia among children and adolescents making this study valuable in addressing a
308 critical knowledge gap that highlights the potential risk of hyperglycemia in younger age groups.
309 Additionally, the inclusion of HbA1c as a diagnostic criterion for hyperglycemia adds to the
310 robustness of the study since HbA1c is a reliable indicator of long-term glucose control and
311 provides a comprehensive assessment of glycemetic status.

312 **Study limitations**

313 The study sites were hospitals based in peri-urban settings posing limitations in generalizability
314 to other settings especially the urban rich who are predisposed to cofounders for hyperglycemia
315 like obesity and sedentary lifestyles.

316 The cross-sectional study design limits ability to establish a causal relationship between
317 hyperglycemia and DTG use. The absence of baseline plasma glucose measurements also
318 hinders determination of the temporal relationship between hyperglycemia and DTG use.

319 The use of consecutive enrollment rather than random sampling and the limitation to participants
320 attending the clinic on a specific day introduces selection bias, potentially affecting the
321 representativeness of the sample.

322 Additionally, the study's sample size was not adequately powered, which may have influenced
323 the study results. The sample size calculation based on prevalence estimates from the adult
324 population may not accurately reflect the prevalence of hyperglycemia in children and

325 adolescents leading to an overestimation or underestimation of the required sample size,
326 potentially affecting the precision and validity of the study findings.

327 The time period for the measurement of Random blood sugar after a meal was not standardized
328 and therefore could have posted a falsely elevated plasma glucose level.

329 The study outcome which was hyperglycemia could have been over or under classified
330 subsequently giving a relatively higher or lower prevalence respectively.

331 **Conclusions**

332 The prevalence of Dolutegravir-related-hyperglycemia is high occurring in every 2 in 10 children
333 and adolescents. The findings highlight the need for increased attention to glycemic screening
334 and monitoring in this population. Health education talks on DTG adverse events were found to
335 be protective against hyperglycemia underscoring the need to develop comprehensive health
336 education messages that address DTG related complications and ensure optimal care for children
337 and adolescents on Dolutegravir-based ART regimens.

338 **Recommendations**

339 Based on the study findings, there should be advocacy for updates in HIV treatment guidelines to
340 include specific recommendations for glycemic screening and monitoring for children and
341 adolescents on Dolutegravir-based ART regimens.

342 The use of glycated hemoglobin (HbA1c) tests, for persons on a DTG based regimen should be
343 supported given its accuracy in monitoring glycemic control over a longer duration.

344 Routine Glycemic screening and monitoring is recommended for children and adolescents on
345 Dolutegravir-based ART regimens to support early detection and management of hyperglycemia.

346 Health Education programs for children, adolescents, and their caregivers should routinely focus
347 on the potential side effects of Dolutegravir, including hyperglycemia with emphasis on the
348 importance of lifestyle modifications, such as healthy eating habits and regular physical activity.
349 To conduct longitudinal studies to investigate the long-term implications of Dolutegravir-related
350 hyperglycemia in children and adolescents while evaluating the progression of hyperglycemia,
351 its impact on metabolic health, and the effectiveness of different management strategies.

352 **Acknowledgements**

353 The authors would like to acknowledge the contribution of Ambrose Okibure for support in the
354 statistical analysis and all the lecturers in the Department of Paediatrics and Child health,
355 Makerere University for their insightful input from concept development to completion of the
356 manuscript. We also appreciate Dr. Ben Watmon and Dr. Nathan Onyachi for providing
357 clearance to conduct the study in Soroti and Lira RRHs.

358

359

360

361

362

363

364

365

366 **References**

- 367 1. The World Health Organisation. Statement on DTG - Geneva 18 May 2018. Who. 2018;
- 368 2. Moore CL, Turkova A, Mujuru H, Kekitiinwa A, Lugemwa A, Kityo CM, et al. ODYSSEY
369 clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-
370 based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to
371 evaluate pragmatic WHO-weight-band based doluteg. BMC Infect Dis. 2021;
- 372 3. McLaughlin M, Walsh S, Galvin S. Dolutegravir-induced hyperglycaemia in a patient living with
373 HIV. Journal of Antimicrobial Chemotherapy. 2018.
- 374 4. Kamal P, Sharma S. SUN-187 Dolutegravir Causing Diabetes. J Endocr Soc.
375 2019;3(Supplement_1).
- 376 5. Lamorde M, Atwiine M, Owarwo NC, Ddungu A, Laker EO, Mubiru F, et al. Dolutegravir-
377 associated hyperglycaemia in patients with HIV. The Lancet HIV. 2020.
- 378 6. Tosur M, Viau-Colindres J, Astudillo M, Redondo MJ, Lyons SK. Medication-induced
379 hyperglycemia: Pediatric perspective. BMJ Open Diabetes Research and Care. 2020.
- 380 7. Song IH, Zong J, Borland J, Jerva F, Wynne B, Zamek-Glisczynski MJ, et al. The effect of
381 dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Acquir Immune Defic
382 Syndr. 2016;
- 383 8. Mercadel CJ, Skelley JW, Kyle JA, Elmore LK. Dolutegravir: An integrase strand transfer
384 inhibitor for the treatment of human immunodeficiency virus I in adults. J Pharm Technol. 2014;
- 385 9. Mooren FC, Krüger K, Völker K, Golf SW, Wadeuhl M, Kraus A. Oral magnesium
386 supplementation reduces insulin resistance in non-diabetic subjects - a double-blind, placebo-
387 controlled, randomized trial. Diabetes, Obesity and Metabolism. 2011.
- 388 10. Paolisso G, Scheen A, D'Onofrio F, Lefèbvre P. Magnesium and glucose homeostasis.
389 Diabetologia. 1990.
- 390 11. Hailu W, Tesfaye T, Tadesse A. Hyperglycemia after dolutegravir-based antiretroviral therapy. Int

- 391 Med Case Rep J. 2021;
- 392 12. Marcovecchio ML. Complications of acute and chronic hyperglycemia. US Endocrinology. 2017.
- 393 13. Dobrica E, Gaman MA, Cozma MA, Gaman AM, Diaconu CC. MACROVASCULAR AND
394 MICROVASCULAR COMPLICATIONS IN TYPE 2 DIABETES MELLITUS. J Hypertens.
395 2019;
- 396 14. Ministry of Health. Consolidated Guidelines for Prevention and Treatment of HIV in Uganda |
397 Ministry of Health Knowledge Management Portal. 2018;(February). Available from:
398 [http://library.health.go.ug/publications/hivaids/consolidated-guidelines-prevention-and-treatment-](http://library.health.go.ug/publications/hivaids/consolidated-guidelines-prevention-and-treatment-hiv-uganda)
399 [hiv-uganda](http://library.health.go.ug/publications/hivaids/consolidated-guidelines-prevention-and-treatment-hiv-uganda)
- 400 15. Sundberg F, Barnard K, Cato A, de Beaufort C, DiMeglio LA, Dooley G, et al. ISPAD Guidelines.
401 Managing diabetes in preschool children. Pediatr Diabetes. 2017;
- 402 16. International Diabetes Federation. Diabetes Atlas, 2019. 9 th ed. Brussels, Belgium: IDF, 2019.
403 2019.
- 404 17. Hirsch-Moverman Y, Howard AA, Mantell JE, Bongomin P, Wu Y, El-Sadr WM, et al. High
405 prevalence of pre-diabetes among people living with HIV in a high TB burden setting.
406 International Journal of Tuberculosis and Lung Disease. 2020.
- 407 18. Odenyo JA, Pharm B. Prevalence of Dolutegravir Associated Hyperglycemia and Its Covariates
408 Among Persons Living With Hiv on Treatment At Kenyatta National Hospital. 2020;21(1):1–13.
- 409 19. Bahamdain FO. Effect of dolutegravir on plasma glucose among human immunodeficiency virus
410 patients in a community health center setting. Int J Community Med Public Heal. 2022;
- 411 20. Namara D, Schwartz JI, Tsubira AK, McFarland W, Birungi C, Semitala FC, et al. The risk of
412 hyperglycaemia associated with the use of dolutegravir among adults living with HIV in Kampala,
413 Uganda: a case-control study. Lancet Glob Heal. 2022;10.
- 414 21. Fitch K V., Anderson EJ, Hubbard JL, Carpenter SJ, Waddell WR, Caliendo AM, et al. Effects of
415 a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS.

- 416 2006;
- 417 22. Robinson FP, Quinn LT, Rimmer JH. Effects of High-Intensity Endurance and Resistance
418 Exercise on HIV Metabolic Abnormalities: A Pilot Study. *Biol Res Nurs*. 2007;
- 419 23. Chawla SS, Kaur S, Bharti A, Garg R, Kaur M, Soin D, et al. Impact of health education on
420 knowledge, attitude, practices and glycemc control in type 2 diabetes mellitus. *J Fam Med Prim
421 Care*. 2019;
- 422 24. C Miiro, GJ Imodia MM. Relationship between hyperglycemia and dolutegravir based HAART
423 and the associated factors at Mbale regional referral hospital: A case-control study. 2022.
- 424 25. Abera MA. Dolutegravir-Associated Hyperglycemia in People Living with Human Immune-
425 Deficiency Virus: A Prospective Cohort Study. *Res Sq*. 2023;
- 426 26. Mulindwa F, Castelnovo B, Brusselaers N, Bollinger R, Rhein J, Edrisa M, et al. Blood glucose
427 trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on
428 dolutegravir. *AIDS Res Ther*. 2023;
- 429